Elsevier

Annals of Oncology

Volume 33, Supplement 7, September 2022, Pages S1401-S1402
Annals of Oncology

LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

https://doi.org/10.1016/j.annonc.2022.08.032Get rights and content
Under an Elsevier user license
open archive

Cited by (0)